Mezavant

Mesalazine, the active ingredient in Mezavant, is a 5-aminosalicylic acid (5-ASA) presented as an oral formulation for gastrointestinal use. It is employed to reduce intestinal inflammation in patients with ulcerative colitis.

GNH USA supplies Mezavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mezavant is a 5‑ASA drug that targets inflammation in the colon associated with ulcerative colitis.

Ulcerative colitis (induction): helps achieve clinical remission by reducing mucosal inflammation. Ulcerative colitis (maintenance): supports sustained remission and lowers relapse risk. Ulcerative colitis (mild to moderate disease): controls symptoms such as bleeding and urgency.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal pain: cramping or discomfort. - Headache: transient tension‑type pain. - Flatulence: increased intestinal gas. - Rash: mild skin irritation. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis, swelling, or hives. - Blood in stool: possible gastrointestinal bleeding. - Elevated liver enzymes: indication of hepatic stress. - Pancreatitis: acute inflammation of the pancreas. - Kidney dysfunction: reduced renal clearance. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.

Before initiating Mezavant, consider patient‑specific factors and monitor appropriately. - Pregnancy: discuss potential risks with a healthcare professional. - Breastfeeding: evaluate benefit‑risk balance before use. - Renal impairment: adjust therapy and monitor renal function. - Hepatic impairment: use with caution and observe liver tests. - Drug interactions: review all concomitant medications. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mezavant may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Azathioprine: increased risk of bone‑marrow suppression. - Warfarin: potential alteration of INR and bleeding risk. - Methotrexate: additive toxicity to liver and marrow.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive efficacy. - Allopurinol: may require dose adjustment and renal monitoring.